Cencora COR is slated to report first-quarter ... respectively. However, the PharmaLex business growth is not keeping up with original expectations as the outsourced pharma services market faces ...

Cencora also acquired PharmaLex, which provides business and consulting support to biopharma firms. While the firm is still working on fully integrating this business, we think it could be another ...

Cencora, Inc. COR is well-poised for growth ... A $418-million goodwill impairment on PharmaLex reflects underperformance in outsourced pharma services due to market pressures.

Over the past year, many Cencora, Inc. ( NYSE:COR ) insiders sold a significant stake in the company which may have... CONSHOHOCKEN, Pa., February 07, 2025--Cencora, Inc. (NYSE: COR) today ...

Feb 5 (Reuters) - Drug distributor Cencora (COR.N), opens new tab raised its fiscal 2025 profit forecast on Wednesday, driven by robust demand for expensive specialty medicines. The Conshohocken ...

Cencora (NYSE:COR) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding ...

Cencora (COR) has significantly expanded the number and type of medications available in its sure supply program, a drug shortage mitigation initiative designed to provide health systems with ...

CONSHOHOCKEN, Pa. — CONSHOHOCKEN, Pa. — Cencora, Inc. (COR) on Wednesday reported fiscal first-quarter net income of $488.6 million. The Conshohocken, Pennsylvania-based company said it had ...

Hello and welcome everyone to the Cencora Q1 fiscal year 2025 earnings call. My name is Becky and I’ll be your Operator today. During the presentation, you can register a question by pressing ...

Baird raised the firm’s price target on Cencora (COR) to $307 from $305 and keeps an Outperform rating on the shares. The firm noted it was another beat and raise quarter. Published first on ...